Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177666 | 1.00 | ANPEP (0.53) | ANPEPERAP1ERAP2TDP1EPHX1 | |
| SCHEMBL1568623 | 1.00 | ANPEP (0.53) | ANPEPERAP1ERAP2TDP1EPHX1 | |
| SCHEMBL6820062 | 0.88 | S1PR2 (0.53) | ANPEPERAP1ERAP2TDP1EPHX1 | |
| SCHEMBL7309652 | 0.88 | S1PR2 (0.53) | ANPEPERAP1ERAP2TDP1EPHX1 | |
| SCHEMBL6820069 | 0.88 | S1PR2 (0.53) | ANPEPERAP1ERAP2TDP1EPHX1 | |
| SCHEMBL4895850 | 0.86 | EPHX1 (0.56) | ANPEPERAP1ERAP2EPHX1CYP2A6 | |
| SCHEMBL28779881 | 0.86 | S1PR2 (0.59) | ANPEPERAP1ERAP2TDP1HTR2A | |
| SCHEMBL7310306 | 0.86 | S1PR2 (0.59) | ANPEPERAP1ERAP2TDP1HTR2A | |
| SCHEMBL19143919 | 0.85 | TDP1 (0.54) | ANPEPERAP1ERAP2TDP1EPHX1 | |
| Methyl Carbamate SCHEMBL28108897 | 0.85 | METAP2 (0.47) | ANPEPERAP1ERAP2SMN1; SMN2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016160677-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016160677-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
| EP-1972615-A1 | CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
| EP-0982026-B1 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | disclosed |
| EP-0876388-B1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2001096319-A1 | TRANS-GLYCOSIDATION PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3A)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-3-(4-FLUOROPHENYL)-1,4-OXAZINE | MERCK & CO., INC. (US) | 2001-12-20 | — | — | WO | disclosed |
| US-6184236-B1 | Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative | HOFFMANN-LA ROCHE INC. | 2001-02-06 | — | — | US | disclosed |
| EP-0982026-A2 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-01 | — | — | EP | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0876388-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0728735-B1 | Process for the preparation of racemic aminoalcohols | DEGUSSA (DE) | 1998-04-01 | — | — | EP | disclosed |
| US-5672753-A | Method of producing racemic amino alcohols | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1997-09-30 | — | — | US | disclosed |
| WO-1997017356-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-05-15 | — | — | WO | disclosed |
| EP-0728735-A1 | Process for the preparation of racemic aminoalcohols | Degussa Aktiengesellschaft (DE) | 1996-08-28 | — | — | EP | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | ANPEP 2578/4885ERAP1 908/4885ERAP2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.